Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response
Nyberg, S.; Nakashima, Y.; Nordström, A.L.; Halldin, C.; Farde, L.
British Journal of Psychiatry. Supplement 1996(29): 40-44
1996
ISSN/ISBN: 0960-5371 PMID: 8733822 Document Number: 465098
Document emailed within 1 workday
Related Documents
Yanai, K.; Ryu, J.H.; Watanabe, T.; Iwata, R.; Ido, T.; Asakura, M.; Matsumura, R.; Itoh, M. 1995: Positron emission tomographic study of central histamine H1-receptor occupancy in human subjects treated with epinastine, a second-generation antihistamine Methods and Findings in Experimental and Clinical Pharmacology 17(Suppl): 64-69Baron, J.C. 1991: In vivo imaging of functional neuroanatomy: positron emission tomography Bulletin de l'Association des Anatomistes 75(229): 85-88
Loken, M.K.; Hawkins, R.A.; Gupta, N.C.; Frick, M.P. 1989: Positron emission tomography (PET): a unique approach for the imaging of in vivo metabolism Nebraska Medical Journal 74(11): 333-339
Strauss, L.G.; Frangos, S.; Dimitrakopoulou-Strauss, A. 2012: Response of calcitonin levels due to positron emission tomography with (18)F-FDG Hellenic Journal of Nuclear Medicine 15(3): 251
Kjaer, A. 2005: Molecular imaging with positron emission tomography and single photon emission computer tomography. Status and perspectives Ugeskrift for Laeger 167(48): 4549-4552
Tsai, M-Hsui.; Huang, W-Sheng.; Tsai, J.J.; Chen, Y-Kung.; Changlai, S-Pin.; Kao, C-Hung. 2003: Differentiating recurrent or residual nasopharyngeal carcinomas from post-radiotherapy changes with 18-fluoro-2-deoxyglucose positron emission tomography and thallium-201 single photon emission computed tomography in patients with indeterminate computed tomography findings Anticancer Research 23(4): 3513-3516
Seitz, U.; Wagner, M.; Vogg, A.T.; Glatting, G.; Neumaier, B.; Greten, F.R.; Schmid, R.M.; Reske, S.N. 2001: In vivo evaluation of 5-[(18)F]fluoro-2'-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model Cancer Research 61(10): 3853-3857
M'Rabet, N.; Lotstra, F.; Goldman, S.; Delvenne, V.; Mendlewicz, J. 1991: Cerebral glucose metabolism in schizophrenia. Studies using positron-emission tomography Acta Psychiatrica Belgica 91(6): 311-326
Schober, O.; Meyer, G.J. 1989: Clinical use of positron emission tomography in tumor patients Zeitschrift für Gastroenterologie. Verhandlungsband 24: 152-154
Kling, M.A.; Carson, R.E.; Borg, L.; Zametkin, A.; Matochik, J.A.; Schluger, J.; Herscovitch, P.; Rice, K.C.; Ho, A.; Eckelman, W.C.; Kreek, M.J. 2000: Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts Journal of Pharmacology and Experimental Therapeutics 295(3): 1070-1076
Mazziotta, J.C. 1988: Practical clinical applications of positron emission tomography in epilepsy American Journal of Physiologic Imaging 3(1): 28-29
Sakai, M.; Kato, H.; Saito, K.; Tanaka, N.; Inose, T.; Kimura, H.; Miyazaki, T.; Kuwano, H. 2008: Clinical applications of 18F-fluorodeoxyglucose positron emission tomography in gastrointestinal stromal tumor of the esophagus International Surgery 93(4): 209-213
Momose, T. 2004: Measurement of brain function by positron emission tomography--clinical application of PET to neurological disorders Rinsho Shinkeigaku 44(11): 897-899
Verhagen, A.; Elsinga, P.H.; de Groot, T.J.; Paans, A.M.; de Goeij, C.J.; Sluyser, M.; Vaalburg, W. 1991: A fluorine-18 labeled progestin as an imaging agent for progestin receptor positive tumors with positron emission tomography Cancer Research 51(7): 1930-1933
Harik, S.I.; Riachi, N.J.; Hritz, M.A.; Berridge, M.S.; Sayre, L.M. 1993: Development of fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs with potent nigrostriatal toxicity for potential use in positron emission tomography studies Journal of Pharmacology and Experimental Therapeutics 266(2): 790-795
Soepenberg, O. 2000: Added value of positron emission tomography with fluoro-18-deoxyglucose as the tracer (FDG-PET) in clinical problem cases in oncology Nederlands Tijdschrift Voor Geneeskunde 144(41): 1979-1980
Sin, A.H.; Gonzalez-Toledo, E.; Fowler, M.; Minagar, A.; Nanda, A. 2008: Amyloidoma presenting as a butterfly glioma on positron emission tomography scan and magnetic resonance-spectroscopy: a case report and review of the literature Journal of the Louisiana State Medical Society: Official Organ of the Louisiana State Medical Society 160(1): 44-7 49-50
Mautner, V.F.; Brenner, W.; Fünsterer, C.; Hagel, C.; Gawad, K.; Friedrich, R.E. 2007: Clinical relevance of positron emission tomography and magnetic resonance imaging in the progression of internal plexiform neurofibroma in NF1 Anticancer Research 27(4a): 1819-1822
Alpay, L.; Lacin, T.; Kanbur, S.; Kiral, H.; Ersoz, E.; Bayram, S.; Dogruyol, T.; Baysungur, V.; Yalcinkaya, I. 2013: Are the 18F-FDG positron emission tomography/computed tomography findings in bronchopulmonary carcinoid tumors different than expected? Hellenic Journal of Nuclear Medicine 16(3): 213-217
Liu, F.-l.; Hong, Q.-y.; Shi, H.-c.; Gu, Y.-c.; Bai, C.-x. 2013: Value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in early diagnosis of lung cancer Zhonghua Yi Xue Za Zhi 93(38): 3019-3022